---
document_datetime: 2024-07-25 11:58:33
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/nulibry-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: nulibry-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.9113352
conversion_datetime: 2025-12-18 22:37:11.684685
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## NULIBRY

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                              | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IAIN/0009            | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site | 24/07/2024                          | n/a                                         |                                  |           |
| IAIN/0008/G          | This was an application for a group of variations.                                                 | 24/07/2024                          |                                             | SmPC, Annex II and PL            |           |

1 Notifications  are issued for  type I variations  and Article  61(3) notifications  (unless part of a group including a type II variation  or extension  application  or a worksharing  application).  Opinions are  issued for all  other procedures.

2 A Commission  decision  (CD) is issued for procedures  that affect  the terms of the marketing  authorisation  (e.g.  summary of  product characteristics,  annex  II, labelling,  package  leaflet).  The CD is issued within two  months of  the opinion  for variations  falling  under the scope of  Article  23.1a(a)  of Regulation  (EU) No.  712/2012, or within  one year  for other procedures.

3 SmPC  (Summary  of Product Characteristics),  Annex  II, Labelling,  PL (Package  Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                     | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing A.1 - Administrative change - Change in the name and/or address of the MAH A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where   |            |     |                                                                                                                                                                                                                                                                  |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/11017 /202308 | Periodic Safety Update EU Single assessment - fosdenopterin                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 11/04/2024 | n/a | PRAC Recommendation - maintenance                                                                                                                                                                                                                                |
| S/0006              | 1st annual re-assessment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 22/02/2024 | n/a | The CHMP, having reviewed the evidence of compliance with the specific obligations and the impact of the data submitted by the MAH on the benefit/risk profile of the medicinal product, concluded that marketing authorisation of NULIBRY should be maintained. |
| PSUSA/11017         | Periodic Safety Update EU Single assessment -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 28/09/2023 | n/a | PRAC Recommendation - maintenance                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

| /202302   | fosdenopterin                       |            |            |                        |
|-----------|-------------------------------------|------------|------------|------------------------|
| T/0004    | Transfer of Marketing Authorisation | 29/06/2023 | 17/07/2023 | SmPC, Labelling and PL |
| T/0002    | Transfer of Marketing Authorisation | 18/11/2022 | 03/02/2023 | SmPC, Labelling and PL |